FDA Approved: JALYN — Supplemental Application (Waylis Therapeutics)

View source ↗

Summary

FDA approved a supplemental application for JALYN, a fixed-dose combination of dutasteride and tamsulosin hydrochloride manufactured by Waylis Therapeutics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia

Drugs mentioned

• JALYN (dutasteride and tamsulosin hydrochloride)

Snippet

SUPPL AP for JALYN (DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE)